Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2012 Aug;12(4):244-51.
doi: 10.1016/j.clml.2012.03.003. Epub 2012 Apr 24.

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

Elias Jabbour  1 , Guillermo Garcia-Manero, Jorge Cortes, Farhad Ravandi, William Plunkett, Varsha Gandhi, Stefan Faderl, Susan O'Brien, Gautam Borthakur, Tapan Kadia, Jan Burger, Marina Konopleva, Mark Brandt, Xuelin Huang, Hagop Kantarjian
Affiliations
Clinical Trial

Twice-daily fludarabine and cytarabine combination with or without gentuzumab ozogamicin is effective in patients with relapsed/refractory acute myeloid leukemia, high-risk myelodysplastic syndrome, and blast- phase chronic myeloid leukemia

Elias Jabbour et al. Clin Lymphoma Myeloma Leuk. 2012 Aug.

Abstract

We evaluated the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP). One hundred seven patients were enrolled. Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery (CRp) of 5%. The overall 4-week mortality rate was 9%. In conclusion, BIDFA is active and safe in heavily pretreated patients with myeloid malignancies.

Background: The purpose of this study was to evaluate the efficacy and safety of the combination of twice-daily fludarabine and cytarabine (BIDFA) in patients with refractory/relapsed acute myeloid leukemia (AML), high-risk myelodysplastic syndromes (MDS), and chronic myeloid leukemia in myeloid blast phase (CML-BP).

Patients and methods: One hundred seven patients with refractory/relapsed AML, intermediate and high-risk MDS, and CML-BP, with a performance status of 3 or less and normal organ function were treated. Patients received fludarabine 15 mg/m(2) intravenously (IV) every 12 hours on days 1 to 5 and cytarabine 0.5 g/m(2) IV over 2 hours every 12 hours on days 1 to 5. Gemtuzumab ozogamicin (GO) was administered at 3 mg/m(2) IV on day 1 in the first 59 patients. Patients with CML-BP were allowed to receive concomitant tyrosine kinase inhibitors.

Results: Overall, 27 (26%) patients responded with a complete remission (CR) rate of 21% and CR without platelet recovery of 5%. The overall 4-week mortality rate was 9%. The CR rates for patients with relapsed AML with first CR duration greater than or equal to 12 months, relapsed AML with first CR duration less than 12 months, and refractory/relapsed AML beyond first salvage were 56%, 26%, and 11%, respectively. With a median follow-up of 7 months, the 6-month event-free survival, overall survival, and complete remission CR duration rates were 18%, 35%, and 70%, respectively.

Conclusion: BIDFA is active with an overall response rate of 26% in a heavily pretreated population. This combination is safe with a low 4-week mortality rate of 9%.

PubMed Disclaimer

Figures

Figure 1
Figure 1
(A) Overall Survival for the Entire Population. (B) Event-Free Survival for the Entire Population. (C) Complete Response Duration Among the 27 Responders
Figure 2
Figure 2
(A) Event-Free Survival by Salvage Number and First Remission Duration for the Entire Population. (B) Overall Survival by Salvage Number and First Remission Duration for the Entire Population
See this image and copyright information in PMC

References

    1. Estey EH. How I treat older patients with AML. Blood. 2000;96:1670–3. - PubMed
    1. Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol. 1993;11:116–24. - PubMed
    1. Gandhi V, Estey E, Du M, et al. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res. 1995;1:169–78. - PubMed
    1. Gandhi V, Estey E, Du M, et al. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy. Clin Cancer Res. 1997;3:1539–45. - PubMed
    1. Estey E, Plunkett W, Dixon D, et al. Variables predicting response to high dose cytosine arabinoside therapy in patients with refractory acute leukemia. Leucemia. 1987;1:580–3. - PubMed

Publication types

MeSH terms